Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Tom_Anderson
|
| gptkbp:developedBy |
AAV-based gene therapies
|
| gptkbp:focusesOn |
rare diseases
neurological diseases |
| gptkbp:foundedYear |
2018
|
| gptkbp:headquartersLocation |
gptkb:Philadelphia,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
SwanBio Therapeutics
|
| gptkbp:industry |
gene therapy
|
| gptkbp:investor |
gptkb:Syncona
gptkb:Longwood_Fund gptkb:Mass_General_Brigham_Ventures |
| gptkbp:program |
SBT101
|
| gptkbp:SBT101Indication |
adrenomyeloneuropathy (AMN)
|
| gptkbp:website |
https://swanbiotx.com/
|
| gptkbp:bfsParent |
gptkb:Two_Bear_Capital
|
| gptkbp:bfsLayer |
8
|